Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline.
Select Content Type
Clinical Guidelines
Authored By
Fairbairn, Nadia , Ross, Josey , Trew, Michael , Meador, Karine , Turnbull, Jeff , MacDonald, Scott , Oviedo-Joekes, Eugenia , Le Foll, Bernard , Goyer, Marie-Eve , Perreault, Michel , Sutherland, Christy
Interests
Internal/Family Medicine
Book Detail
Publisher
Canadian Medical Association
volume
191
ISSN
1488-2329 ; Electronic
Actions
Download in App
Event Data
{"article_title":"Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline.","author":"Fairbairn, Nadia , Ross, Josey , Trew, Michael , Meador, Karine , Turnbull, Jeff , MacDonald, Scott , Oviedo-Joekes, Eugenia , Le Foll, Bernard , Goyer, Marie-Eve , Perreault, Michel , Sutherland, Christy","journal_title":"CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne","issn":"1488-2329 ; Electronic","isbn":"","publication_date":"20190923","volume":"191","issue":"38","first_page":"E1049","page_count":"","accession_number":"31548191","doi":"10.1503\/cmaj.190344","publisher":"Canadian Medical Association","doctype":"Journal Article; Practice Guideline","subjects":"Medicine ","interest_area":["Internal\/Family Medicine"],"abstract":"Competing interests: Marie-Eve Goyer reports receiving an honorarium and training from Gilead Sciences, outside of the submitted work. Bernard Le Foll reports receiving grants from Pfizer and Brainsway, Bioprojet, Alkermes, Canopy and the American Chemical Society, as well as nonfinancial support from Aurora, outside the submitted work. Josey Ross is employed by the BC Centre on Substance Use, the British Columbia node of the Canadian Research Initiative in Substance Misuse (CRISM). Christy Sutherland is employed by the BC Centre on Substance Use and is also the medical director of PHS Community Services Society, which provides injectable opioid agonist treatment. Michael Trew works for Alberta Health Services; the development of injectable opioid agonist treament clinics in Alberta have been partially funded through specific grants from the Alberta Ministry of Health for this work. Nadia Fairbairn reports receiving personal fees from British Columbia Centre on Substance Use, during the conduct of the study. No other competing interests were declared.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=31548191&authtype=shib&custid=ns346513"}
Competing interests: Marie-Eve Goyer reports receiving an honorarium and training from Gilead Sciences, outside of the submitted work. Bernard Le Foll reports receiving grants from Pfizer and Brainsway, Bioprojet, Alkermes, Canopy and the American Chemical Society, as well as nonfinancial support from Aurora, outside the submitted work. Josey Ross is employed by the BC Centre on Substance Use, the British Columbia node of the Canadian Research Initiative in Substance Misuse (CRISM). Christy Sutherland is employed by the BC Centre on Substance Use and is also the medical director of PHS Community Services Society, which provides injectable opioid agonist treatment. Michael Trew works for Alberta Health Services; the development of injectable opioid agonist treament clinics in Alberta have been partially funded through specific grants from the Alberta Ministry of Health for this work. Nadia Fairbairn reports receiving personal fees from British Columbia Centre on Substance Use, during the conduct of the study. No other competing interests were declared.